WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Sports betting roundup: Xander Schauffele's final putt pays off for bettors
Gambling bill to allow lottery and slots remains stalled in the Alabama Senate
Stanton and Rizzo help Yankees rally in 9th inning for 2
Alec Bohm, Brandon Marsh lead surging Phillies to 4
Rockies lead from start to finish for the first time this year in 3
Angels star outfielder Mike Trout has knee surgery. Team expects 3
Arizona GOP wins state high court appeal of sanctions for 2020 election challenge
Socialite Jasmine Hartin enjoys beach snuggle with electrician hunk
California man who testified against Capitol riot companion is sentenced to home detention
Harris accepts debate invite to face off with Trump's VP pick, which may come at convention
Power blackouts hit Tanzania as Cyclone Hidaya intensifies